EUVIMEDEUVIMED entdecken
Crossref

Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation

Dan Liu, Jianting Zhan, Shiqin Wang, Lvyi Chen, Qianqian Zhu, Ruili Nie, Xuxiang Zhou, Wuyinxiao Zheng, Xin Luo, Bo Wang, Jing Nie, Xiaochuan Ye

Phytomedicine · 2024-07 · 130 · 155774

DOI: 10.1016/j.phymed.2024.155774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024-07. Verfasst von Dan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; H…. Hauptthemen laut MEDLINE: Chrysanthemum, Gastrointestinal Microbiome, PPAR gamma, PPAR alpha. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Metabolic and alcohol-associated liver disease (MetALD) shows a high prevalence rate in liver patients, but there is currently no effective treatment for MetALD. As a typical edible traditional Chinese medicinal herb, the anti-inflammatory, antioxidant, and hepatoprotective properties of water extract of Chrysanthemum morifolium Ramat. (WECM) has been demonstrated. However, its therapeutic effect on MetALD and the associated mechanisms remain unclear. PURPOSE: To investigate the underlying mechanisms of WECM against MetALD. METHODS: We constructed a MetALD rat model following a high-fat & high-sucrose plus alcohol diet (HFHSAD). MetALD rats were treated with WECM at 2.1, 4.2, and 8.4 g/kg/d for six weeks. Efficacy was determined, and pathways associated with WECM against MetALD were predicted through serum and hepatic biochemical marker measurement, histopathological section analysis, 16S rDNA sequencing of the gut microbiota and untargeted serum metabolomics analyses. Changes in genes and proteins in the peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ) signaling pathways were detected by RT‒PCR and Western blotting. RESULTS: WECM treatment significantly attenuated hepatic steatosis, hyperlipidemia and markers of liver injury in MetALD rats. Moreover, WECM improved vascular endothelial function, hypertension, and systematic oxidative stress. Mechanistically, WECM treatment altered the overall structure of the gut microbiota through maintaining Firmicutes/Bacteroidota ratio and reducing harmful bacterial abundances such as Clostridium, Faecalibaculum, and Herminiimonas. Notably, WECM promoted 15-deoxy-△12, 14-prostaglandin J2 (15d-PGJ2) release and further activated the PPARγ to reduce serum TNF-α, IL-1β, and IL-6 levels. Additionally, WECM upregulated PPARα and downregulated the levels of CD36 and FABP4 to improve lipid metabolism. CONCLUSION: Our findings provide the first evidence that WECM treatment significantly improved hepatic steatosis, oxidative stress and inflammation in MetALD rats by regulating the gut microbiota and activating the 15d-PGJ2/PPARγ and PPARα signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChrysanthemumGastrointestinal MicrobiomePPAR gammaPPAR alphaLiver Diseases, AlcoholicRats, Sprague-DawleyAnimalsMaleDiet, High-FatRatsLiverPlant ExtractsDisease Models, AnimalSignal TransductionDrugs, Chinese HerbalOxidative Stress

Stichwörter der Autor:innen

Chrysanthemum morifolium Ramat.Gut microbiotaMetabolic and alcohol-associated liver diseaseMetabonomicsPeroxisome proliferator-activated receptor alpha/gamma

Substanzen

PPAR gammaPPAR alphaPlant ExtractsDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Shizhen Laboratory, Hubei University of Chinese Medicine, Wuhan 4…
  • Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
  • School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan 430074, China.
  • Key Laboratory of Chinese Medicine Quality Control of State Drug Administration, Hubei Institute for Drug Control, Wuhan 430075, China.
  • Hubei Center for ADR Monitoring, Wuhan 430071, China.

Zitieren

APA

Liu, D., Zhan, J., Wang, S., Chen, L., Zhu, Q., Nie, R., Zhou, X., Zheng, W., Luo, X., Wang, B., Nie, J., & Ye, X. (2024). Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation. Phytomedicine, 130, 155774. https://doi.org/10.1016/j.phymed.2024.155774

Vancouver

Liu D, Zhan J, Wang S, Chen L, Zhu Q, Nie R, et al. Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation. Phytomedicine. 2024;130:155774. doi:10.1016/j.phymed.2024.155774

BibTeX
@article{Liu2024,
  author = {Liu, Dan and Zhan, Jianting and Wang, Shiqin and Chen, Lvyi and Zhu, Qianqian and Nie, Ruili and Zhou, Xuxiang and Zheng, Wuyinxiao and Luo, Xin and Wang, Bo and Nie, Jing and Ye, Xiaochuan},
  title = {Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation},
  journal = {Phytomedicine},
  year = {2024},
  volume = {130},
  pages = {155774},
  doi = {10.1016/j.phymed.2024.155774}
}
Kostenlos starten →